4/9
08:49 am
dcoy
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline [TheStreet.com]
Low
Report
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline [TheStreet.com]
4/9
08:36 am
dcoy
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Medium
Report
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
4/6
09:42 am
dcoy
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 [Yahoo! Finance]
Low
Report
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 [Yahoo! Finance]
4/6
09:25 am
dcoy
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 [TheStreet.com]
Medium
Report
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 [TheStreet.com]
4/6
09:15 am
dcoy
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Medium
Report
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
4/2
09:13 am
dcoy
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement [TheStreet.com]
Medium
Report
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement [TheStreet.com]
4/2
09:00 am
dcoy
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
High
Report
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
3/31
11:35 am
dcoy
DeuteRx Celebrates Women's History Month with Over a Decade of Pioneering Leadership in Drug Discovery [Yahoo! Finance]
Low
Report
DeuteRx Celebrates Women's History Month with Over a Decade of Pioneering Leadership in Drug Discovery [Yahoo! Finance]
3/11
08:30 am
dcoy
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
High
Report
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
3/5
08:30 am
dcoy
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
Medium
Report
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
2/11
09:00 am
dcoy
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
Low
Report
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
2/5
09:54 am
dcoy
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial [Yahoo! Finance]
Medium
Report
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial [Yahoo! Finance]
2/5
09:15 am
dcoy
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Low
Report
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
2/4
09:02 am
dcoy
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Medium
Report
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
1/23
05:06 pm
dcoy
Decoy Therapeutics (NASDAQ:DCOY) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
Low
Report
Decoy Therapeutics (NASDAQ:DCOY) is now covered by analysts at
Weiss Ratings. They set a "sell (e)" rating on the stock.
1/23
08:04 am
dcoy
Decoy Therapeutics (NASDAQ:DCOY) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $2.50 price target on the stock.
Low
Report
Decoy Therapeutics (NASDAQ:DCOY) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating and a $2.50 price target on the stock.